SNMMI: FDOPA-PET/MRI monitors pediatric brain tumors

June 9, 2015

Clinicians may soon be able to add PET/MRI with F-18 fluorodopa (FDOPA) to their imaging arsenal to evaluate the efficacy of the angiogenesis inhibitor bevacizumab for pediatric brain tumors, according to a study presented on Monday at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting.

Researchers from Washington University in St. Louis found that using the amino acid tracer FDOPA with PET/MRI is a feasible way to visualize recurrent brain tumors in pediatric patients and evaluate changes in metabolic tumor volume after one cycle (four weeks) or more of bevacizumab therapy.

Full Story